WallStreetZenWallStreetZen

NYSEMKT: APUS
Apimeds Pharmaceuticals Us Revenue

OverviewEarningsRevenue
DividendOwnership
Apimeds Pharmaceuticals Us revenue was $0.00 for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $0.0, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, APUS annual revenue was $0.0, with N/A growth year-over-year.

APUS revenue history

Current Revenue
$0.0
Current Earnings
-$1.4M
Current Profit Margin
0%

Be the first to know when APUS announces revenue.

APUS Revenue History By Year

APUS Yearly RevenueAPUS RevenueAPUS ChangeAPUS Revenue Growth
2024-12-31$0.00N/AN/A
2023-12-31$0.00N/AN/A
2022-12-31$0.00N/AN/A

1 of 1

Apimeds Pharmaceuticals Us Revenue FAQ

What was APUS's revenue last quarter?

Apimeds Pharmaceuticals Us (NYSEMKT: APUS) reported Q4 2024 revenue of $0.00 up N/A year over year. In the same quarter last year, Apimeds Pharmaceuticals Us's revenue was $0.00.

What was Apimeds Pharmaceuticals Us's revenue in 2024?

Apimeds Pharmaceuticals Us's annual revenue for the twelve months ending Dec 31, 2024 was $0.00, a N/A decrease year over year.

How much does Apimeds Pharmaceuticals Us make in a day?

Based on Apimeds Pharmaceuticals Us annual revenue for the past two years, APUS makes an average of $0.00 per day.

What was Apimeds Pharmaceuticals Us's annual revenue growth in the past year?

As of Q2 2025, Apimeds Pharmaceuticals Us's revenue has grown null year over year. Apimeds Pharmaceuticals Us's revenue in the past year totaled $0.00.

How much does Apimeds Pharmaceuticals Us make in a year?

Apimeds Pharmaceuticals Us's revenue by year for the past two years is:
  • Apimeds Pharmaceuticals Us's revenue for the twelve months ending Dec 31, 2024 was $0.00, a N/A decrease year over year.
  • Apimeds Pharmaceuticals Us's annual revenue for Dec 31, 2023 was $0.00, a N/A decrease from 2022.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.